Gino Kim In, MD, a medical oncologist, Medical Oncology, Melanoma Surgery, Sarcoma and Melanoma Surgery and associate professor of clinical medicine at Keck School of Medicine of the University of Southern California, discussed the safety and efficacy of superficial and deep or visceral vusolimogene oderparepvec (RP1) injection in a registrational cohort of patients from the phase 3 IGNYTE trial (NCT03767348) with melanoma who progressed on anti–PD-1 inhibitors.
Of Interest
Reduction in length of immunotherapy treatment for hard-to-treat melanoma shows promise in clinical trial
Reducing the length of immunotherapy treatment for an advanced skin cancer did not significantly diminish disease control when compared to giving treatments over a longer period, according to new research led by the Universities of Sheffield.
Dostarlimab/Cobolimab Combo for Melanoma Shows Promise & Tolerability
The primary analysis of the phase 2 NEO-MEL-T study (NCT04139902) evaluating the neoadjuvant therapy of dostarlimab (Jemperli) plus the anti-TIM-3 agent cobolimab in high-risk resectable melanoma was presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting as a late-breaking abstract.
High-fiber diet could improve response to immunotherapy for patients with melanoma
A high-fiber diet increased response to immunotherapy for patients with melanoma compared with a normal healthy diet.